RFID still garners big forecast

Vendors are offering pilot kits to help drugmakers get a handle on the little understood business case for RFID technology. Delays in retailer and regulatory supply chain mandates have hampered adoption, says GBI Research, which forecasts annual industry growth of 34 percent through 2015, in a $3,500 report. Release

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.